Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.12122/j.issn.1673-4254.2020.04.22 http://scihub22266oqcxt.onion/10.12122/j.issn.1673-4254.2020.04.22 C7225120!7225120!32895128     free     free     free       Nan+Fang+Yi+Ke+Da+Xue+Xue+Bao 2020 ; 40 (4): 586-94 Nephropedia Template TP {{tp|p=32895128|t=2020. ????????????????? |pdf=|usr=}}{{32895128}} gab.com Text JO: Nan Fang Yi Ke Da Xue Xue Bao http://www.kidney.de/pget.php?&tw=1&pmid=32895128 #FOAvip Since the outbreak of coronavirus disease 2019 (COVID-19) in the late 2019, a variety of antiviral drugs have been used in the first-line clinical trial. The Diagnostic and Treatment Protocol for COVID-19 (Trial Version 6) in China recommends chloroquine phosphate for the first time as an anti-coronavirus trial drug. As a classic drug for treatment of malaria and rheumatism, chloroquine phosphate has been used clinically for more than 80 years, and has also shown good results in the treatment of various viral infections. As the plasma drug concentration varies greatly among different races and individuals and due to its narrow treatment window, chloroquine in likely to accumulate in the body to cause toxicity. Among the treatment regimens recommended for COVID-19, reports concerning the safety of a short-term high-dose chloroquine regimen remain scarce. In this review, the authors summarize the current research findings of chloroquine phosphate in the treatment of COVID-19, and examine the pharmacokinetic characteristics, antiviral therapy, the therapeutic mechanism and safety of chloroquine. Twit Text FOAVip ????Nan Fang Yi Ke Da Xue Xue Bao http://www.kidney.de/pget.php?&tw=1&pmid=32895128 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32895128 #FOAvip English Wikipedia <ref>{{Cite pmid|32895128}}</ref> ????????????????? #MMPMID32895128 ä Nan Fang Yi Ke Da Xue Xue Bao 2020[Apr]; 40 (4): 586-94 PMID32895128show ga Since the outbreak of coronavirus disease 2019 (COVID-19) in the late 2019, a variety of antiviral drugs have been used in the first-line clinical trial. The Diagnostic and Treatment Protocol for COVID-19 (Trial Version 6) in China recommends chloroquine phosphate for the first time as an anti-coronavirus trial drug. As a classic drug for treatment of malaria and rheumatism, chloroquine phosphate has been used clinically for more than 80 years, and has also shown good results in the treatment of various viral infections. As the plasma drug concentration varies greatly among different races and individuals and due to its narrow treatment window, chloroquine in likely to accumulate in the body to cause toxicity. Among the treatment regimens recommended for COVID-19, reports concerning the safety of a short-term high-dose chloroquine regimen remain scarce. In this review, the authors summarize the current research findings of chloroquine phosphate in the treatment of COVID-19, and examine the pharmacokinetic characteristics, antiviral therapy, the therapeutic mechanism and safety of chloroquine. ä????????????????? (epmc).pdf DeepDyve Pubget Overpricing